Granulocyte transfusion in the G-CSF era

Area of Science:

• Hematology
• Transfusion Medicine
• Immunology

Background:

• Granulocyte transfusions have a history of variable success in treating infections in neutropenic patients.
• Previous methods using apheresis and corticosteroids yielded insufficient neutrophil doses (20-30 x 10^9) for established infections.
• Efficacy of granulocyte transfusions is linked to the delivered dose of neutrophils.

Purpose of the Study:

• To evaluate the efficacy of granulocyte transfusions enhanced by G-CSF administration to healthy donors.
• To assess the yield, functional capacity, and safety of G-CSF-primed granulocytes.

Main Methods:

• Healthy donors received G-CSF to stimulate granulocyte production.
• Granulocytes were collected using modern apheresis techniques.
• In vitro and in vivo studies assessed the function and recipient neutrophil counts post-transfusion.

Main Results:

• G-CSF administration to donors resulted in significantly higher granulocyte yields (up to 8 x 10^10 cells).
• Transfused G-CSF-primed granulocytes restored normal or near-normal neutrophil counts in recipients, sustained for up to 24 hours.
• G-CSF-primed granulocytes demonstrated normal function in vitro and in vivo; adverse effects were similar to traditional transfusions.

Conclusions:

• G-CSF-primed granulocyte transfusions offer a substantially higher yield of neutrophils compared to conventional methods.
• The transfused cells appear functionally normal and safe, with comparable adverse effects to standard granulocyte transfusions.
• Further controlled clinical trials are necessary to confirm the therapeutic efficacy of this enhanced granulocyte transfusion strategy.